Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Testing for t(3;8) in MYC/BCL6-rearranged large B-cell lymphoma identifies a high-risk subgroup with inferior survival

Blood (2024) 144 (1): 113–117.

https://doi.org/10.1182/blood.2024024048

Published: 2024

Includes: Supplemental data

Journal Articles

A New Murine Model for B Cell Malignancies on ATM-Deficient Background Reveals Involvement of Multiple Pathogenic Mechanisms

Tegan A Francis, PhD, Nicholas J Davies, PhD, Michael John Griffiths, BSc, Angelo Agathanggelou, PhD, Maha Ibrahim, Paul G. Murray, PhD, Zbigniew Rudzki, Tatjana Stankovic, MD PhD, Alexander M R Taylor, PhD

Blood (2016) 128 (22): 4093.

https://doi.org/10.1182/blood.V128.22.4093.4093

Published: 2016

Journal Articles

The Ataxia Telangiectasia Nude Mouse with No Risk of Thymoma: A Model to Investigate Tumour Development of B Cell and Myeloid Origin Associated with ATM Loss

Tatjana Stankovic, MD, PhD, Phil Byrd, Tegan Francis, Teresa Marafioti, Zbigniew Rudzki, Alexander MR Taylor

Blood (2012) 120 (21): 1320.

https://doi.org/10.1182/blood.V120.21.1320.1320

Published: 2012

Journal Articles

The PARP inhibitor olaparib induces significant killing of ATM -deficient lymphoid tumor cells in vitro and in vivo

Victoria J. Weston, Ceri E. Oldreive, Anna Skowronska, David G. Oscier, Guy Pratt, Martin J. S. Dyer, Graeme Smith, Judy E. Powell, Zbigniew Rudzki, Pamela Kearns, Paul A. H. Moss, A. Malcolm R. Taylor, Tatjana Stankovic

Blood (2010) 116 (22): 4578–4587.

https://doi.org/10.1182/blood-2010-01-265769

Published: 2010

Includes: Supplemental data

Journal Articles

The Initial Molecular Response of Chronic Phase CML Patients Treated with Second Generation ABL Inhibitor Therapy after Imatinib Failure Can Predict Inadequate Response and Provide Indications for Rational Mutation Screening

Susan Branford, Rebecca Lawrence, Linda Fletcher, Chani Field, Zbigniew Rudzki, Timothy Hughes

Blood (2008) 112 (11): 331.

https://doi.org/10.1182/blood.V112.11.331.331

Published: 2008

Journal Articles

Long Term Follow up of Patients with CML in Chronic Phase Treated with First-Line Imatinib Suggests That Earlier Achievement of a Major Molecular Response Leads to Greater Stability of Response.

Susan Branford, Rebecca Lawrence, Andrew Grigg, John Francis Seymour, MBBS, Anthony Schwarer, Christopher Arthur, Zbigniew Rudzki, Timothy Hughes

Blood (2008) 112 (11): 2113.

https://doi.org/10.1182/blood.V112.11.2113.2113

Published: 2008

Journal Articles

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials

Susan Branford, Linda Fletcher, Nicholas C. P. Cross, Martin C. Müller, Andreas Hochhaus, Dong-Wook Kim, Jerald P. Radich, Giuseppe Saglio, Fabrizio Pane, Suzanne Kamel-Reid, Y. Lynn Wang, Richard D. Press, Kevin Lynch, Zbigniew Rudzki, John M. Goldman, Timothy Hughes

Blood (2008) 112 (8): 3330–3338.

https://doi.org/10.1182/blood-2008-04-150680

Published: 2008

Journal Articles

Tonsillar CD38 + Activated B Cell Fraction Harbours the Highest EBV Load in Patients with Infectious Mononucleosis.

Sridhar Chaganti, Andrew Bell, Emily Heath, Wolfgang Bergler, Michael Kuo, Jane Starczynski, Zbigniew Rudzki, Alan Rickinson

Blood (2007) 110 (11): 2277.

https://doi.org/10.1182/blood.V110.11.2277.2277

Published: 2007

Journal Articles

C-met Receptor as a Potential Target for the Treatment of Patients with Multiple Myeloma.

Marcin Majka, PhD, Artur Jurczyszyn, MD, PhD, Anna Zebzda, MSci, Wojciech Czogala, MD, Ewa Lesko, MSci, Zbigniew Rudzki, MD, PhD, Jolanta Gozdzik, MD, PhD, Teresa Wolska-Smolen, MD, PhD, Aleksander B. Skotnicki, MD, PhD, Mariusz Z. Ratajczak, MD, PhD

Blood (2005) 106 (11): 3395.

https://doi.org/10.1182/blood.V106.11.3395.3395

Published: 2005

Journal Articles

Pre-Imatinib Factors Can Be Used To Define the Risk of BCR-ABL Mutations for Patients with CML in Chronic Phase and Identify a Minority Who Should Have Regular Mutation Screening.

Susan Branford, Zbigniew Rudzki, Kevin Lynch, Timothy Hughes

Blood (2005) 106 (11): 1079.

https://doi.org/10.1182/blood.V106.11.1079.1079

Published: 2005

Journal Articles

Impaired Clonogenic Capacity Contributes to Bone Marrow Hypoplasia and Late Hematological Recovery after Zevalin in the Low-Grade NHL Patients.

Wojciech Jurczak, Marta Szostek, Zbigniew Rudzki, Dorota Krochmalczyk, Joanna Wegrzyn, Jaroslaw Czyz, Aleksander B. Skotnicki

Blood (2004) 104 (11): 4610.

https://doi.org/10.1182/blood.V104.11.4610.4610

Published: 2004

Journal Articles

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations

Susan Branford, Zbigniew Rudzki, Ian Parkinson, Andrew Grigg, Kerry Taylor, John F. Seymour, Simon Durrant, Peter Browett, Anthony P. Schwarer, Chris Arthur, John Catalano, Michael F. Leahy, Robin Filshie, Kenneth Bradstock, Richard Herrmann, David Joske, Kevin Lynch, Tim Hughes

Blood (2004) 104 (9): 2926–2932.

https://doi.org/10.1182/blood-2004-03-1134

Published: 2004

Journal Articles

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

Susan Branford, Zbigniew Rudzki, Sonya Walsh, Ian Parkinson, Andrew Grigg, Jeff Szer, Kerry Taylor, Richard Herrmann, John F. Seymour, Chris Arthur, David Joske, Kevin Lynch, Tim Hughes

Blood (2003) 102 (1): 276–283.

https://doi.org/10.1182/blood-2002-09-2896

Published: 2003

Journal Articles

High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

Susan Branford, Zbigniew Rudzki, Sonya Walsh, Andrew Grigg, Chris Arthur, Kerry Taylor, Richard Herrmann, Kevin P. Lynch, Timothy P. Hughes

Blood (2002) 99 (9): 3472–3475.

https://doi.org/10.1182/blood.V99.9.3472

Published: 2002

NARROW

Testing for t(3;8) in MYC/BCL6-rearranged large B-cell lymphoma identifies a high-risk subgroup with inferior survival

A New Murine Model for B Cell Malignancies on ATM-Deficient Background Reveals Involvement of Multiple Pathogenic Mechanisms

The Ataxia Telangiectasia Nude Mouse with No Risk of Thymoma: A Model to Investigate Tumour Development of B Cell and Myeloid Origin Associated with ATM Loss

The PARP inhibitor olaparib induces significant killing of ATM -deficient lymphoid tumor cells in vitro and in vivo

The Initial Molecular Response of Chronic Phase CML Patients Treated with Second Generation ABL Inhibitor Therapy after Imatinib Failure Can Predict Inadequate Response and Provide Indications for Rational Mutation Screening

Long Term Follow up of Patients with CML in Chronic Phase Treated with First-Line Imatinib Suggests That Earlier Achievement of a Major Molecular Response Leads to Greater Stability of Response.

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials

Tonsillar CD38 + Activated B Cell Fraction Harbours the Highest EBV Load in Patients with Infectious Mononucleosis.

C-met Receptor as a Potential Target for the Treatment of Patients with Multiple Myeloma.

Pre-Imatinib Factors Can Be Used To Define the Risk of BCR-ABL Mutations for Patients with CML in Chronic Phase and Identify a Minority Who Should Have Regular Mutation Screening.

Impaired Clonogenic Capacity Contributes to Bone Marrow Hypoplasia and Late Hematological Recovery after Zevalin in the Low-Grade NHL Patients.

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only